Sultana Tania, Lee Soojung, Yoon Hun-Young, Lee Jeong Ik
Regenerative Medicine Laboratory, Center for Stem Cell Research, Department of Biomedical Science and Technology, Institute of Biomedical Science and Technology, Konkuk University, Seoul, Republic of Korea.
Regeniks Co. Ltd., Seoul, Republic of Korea.
Stem Cells Int. 2018 Jul 15;2018:8329174. doi: 10.1155/2018/8329174. eCollection 2018.
Stem cell therapy has prompted the expansion of veterinary medicine both experimentally and clinically, with the potential to contribute to contemporary treatment strategies for various diseases and conditions for which limited or no therapeutic options are presently available. Although the application of various types of stem cells, such as bone marrow-derived mesenchymal stem cells (BM-MSCs), adipose tissue-derived mesenchymal stem cells (AT-MSCs), and umbilical cord blood-derived mesenchymal stem cells (UCB-MSCs), has promising potential to improve the health of different species, it is crucial that the benefits and drawbacks are completely evaluated before use. Umbilical cord blood (UCB) is a rich source of stem cells; nonetheless, isolation of mesenchymal stem cells (MSCs) from UCB presents technical challenges. Although MSCs have been isolated from UCB of diverse species such as human, equine, sheep, goat, and canine, there are inherent limitations of using UCB from these species for the expansion of MSCs. In this review, we investigated canine UCB (cUCB) and compared it with UCB from other species by reviewing recent articles published from February 2003 to June 2017 to gain an understanding of the limitations of cUCB in the acquisition of MSCs and to determine other suitable sources for the isolation of MSCs from canine. Our review indicates that cUCB is not an ideal source of MSCs because of insufficient volume and ethical issues. However, canine reproductive organs discarded during neutering may help broaden our understanding of effective isolation of MSCs. We recommend exploring canine reproductive and adipose tissue rather than UCB to fulfill the current need in veterinary medicine for the well-designed and ethically approved source of MSCs.
干细胞疗法在实验和临床方面都推动了兽医学的发展，有可能为目前治疗选择有限或没有治疗选择的各种疾病和病症的当代治疗策略做出贡献。尽管各种类型的干细胞，如骨髓间充质干细胞（BM-MSCs）、脂肪组织间充质干细胞（AT-MSCs）和脐带血间充质干细胞（UCB-MSCs）的应用，具有改善不同物种健康状况的潜在前景，但在使用前全面评估其利弊至关重要。脐带血（UCB）是丰富的干细胞来源；然而，从UCB中分离间充质干细胞（MSCs）存在技术挑战。尽管已从人类、马、绵羊、山羊和犬等不同物种的UCB中分离出MSCs，但使用这些物种的UCB来扩增MSCs存在固有局限性。在本综述中，我们通过回顾2003年2月至2017年6月发表的近期文章，对犬脐带血（cUCB）进行了研究，并将其与其他物种的UCB进行比较，以了解cUCB在获取MSCs方面的局限性，并确定从犬类中分离MSCs的其他合适来源。我们的综述表明，由于体积不足和伦理问题，cUCB不是MSCs的理想来源。然而，绝育时丢弃的犬类生殖器官可能有助于拓宽我们对有效分离MSCs的理解。我们建议探索犬类生殖组织和脂肪组织，而不是UCB，以满足兽医学目前对设计良好且经伦理批准的MSCs来源的需求。
